PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Excellus BlueCross BlueShieldAll Plans · Coverage · Transplants · NY · Transplant Surgery, GastroenterologyMedium impact

Liver Transplantation 7.02.07

Effective date
Nov 20, 2025
Identified
Jun 20, 2026

Summary

Excellus BlueCross BlueShield policy 7.02.07 covers liver transplantation for selected people with end-stage liver disease when criteria are met. Listed indications include alcoholic cirrhosis, viral hepatitis, autoimmune hepatitis, primary hepatocellular carcinoma when the disease is organ confined and the patient is not a candidate for subtotal liver resection, and familial amyloid polyneuropathy. Cadaver recipients need a MELD score of 9 or greater, and living donor recipients need a MELD score from 9 to 25, a listing on the cadaveric liver transplant waiting list, and at least one significant complication of liver disease. The current effective date is November 20, 2025, and the policy history records an annual review with the policy intent unchanged.

Get alerts when payers change rules like this one

We check Excellus BlueCross BlueShield and other payers every day and email you when a change matches your specialty and state.

Get Excellus BlueCross BlueShield alertsPolicy Monitoring is free. No card required.

What to do

Action · 7 steps
01REQUIREMENTS: Prior authorization is contract dependent, and approvals for all transplants, including arrangements with an approved transplant center, may be required.
02Pre-transplant evaluation documentation could include confirmation of diagnosis, comorbidities and their treatment, consult notes, a Karnofsky or Palliative Performance Scale score, identification of stressors, an oral health evaluation, a CBC and metabolic profile, CMV and hepatitis B and C serologies, HIV testing, a 12 lead EKG, stress testing, an echo or MUGA scan, a chest x-ray, pulmonary function tests for high-risk patients, and a low dose screening CT for high-risk lung cancer patients.
03If a test cannot be performed, the documentation must include the rationale.
04Re-authorization must be completed annually while the patient is actively waiting for a transplant, with documentation from within the past 11 months unless specified, including updated diagnoses and treatment plan, a current Karnofsky or Palliative Performance Scale score, a follow-up oral health evaluation, a CBC and metabolic profile, CMV and hepatitis B and C serologies, and HIV testing if applicable.
05For candidates with end-stage disease related to or impacted by alcohol consumption, including viral hepatitis, abstinence must be shown through clinical treatment records such as primary care or alcohol treatment program records.
06If abstinence has lasted less than one month, a medical director consultation with the transplant center behavioral health team is required, including an assessment by a trained Alcohol and Addiction Professional.
07For candidates listed at more than one transplant center, test results used at one center should be used at subsequent centers when possible.

Codes mentioned

47133471354714047141471424714347144471454714647147A52.15B25.1B66.1B66.3C22.0D81.810D84.1E74.39E88.89E88.9G60.0G60.2G63I82.0I99.9K74.0K75.9K76.4K77K87M34.83Q44.6S31.609AS36.112A

Original notice

Liver Transplantation 7.02.07
excellusbcbs.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account